Koers RegeneRx Biopharmaceuticals, Inc. Other OTC
Aandelen
RGRX
US75886X1081
Farmaceutische producten
Omzet 2021 | 76,76K 72,03K | Omzet 2022 | 76,76K 72,03K | Marktkapitalisatie | 19,94 mln. 18,71 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -1 mln. -938K | Nettowinst (verlies) 2022 | -1 mln. -938K | EV/omzet 2021 | 298 x |
Nettoliquiditeiten 2021 | 66,69K 62,58K | Nettoschuld 2022 | 1,16 mln. 1,08 mln. | EV/omzet 2022 | 275 x |
K/w-verhouding 2021 |
-13,9
x | K/w-verhouding 2022 |
-11,5
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 55,86% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 86 | 13-05-82 | |
J. Finkelstein
CEO | Chief Executive Officer | 72 | 01-01-84 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
J. Finkelstein
CEO | Chief Executive Officer | 72 | 01-01-84 |
Founder | 86 | 13-05-82 | |
Joe McNay
BRD | Director/Board Member | 90 | 01-01-02 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-3,72% | 87,17 mld. | |
+2,76% | 40,1 mld. | |
-16,98% | 31,38 mld. | |
+57,86% | 25,12 mld. | |
-16,24% | 15,59 mld. | |
-9,12% | 12 mld. | |
-42,56% | 11,8 mld. | |
-17,10% | 11,8 mld. | |
+6,89% | 8,81 mld. |